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Abstract
RNA modifications have recently emerged as critical posttranscriptional regulators of gene expression programmes.
Significant advances have been made in understanding the functional role of RNA modifications in regulating
coding and non-coding RNA processing and function, which in turn thoroughly shape distinct gene expression
programmes. They affect diverse biological processes, and the correct deposition of many of these modifications is
required for normal development. Alterations of their deposition are implicated in several diseases, including
cancer. In this Review, we focus on the occurrence of N6-methyladenosine (m6A), 5-methylcytosine (m5C) and
pseudouridine (Ψ) in coding and non-coding RNAs and describe their physiopathological role in cancer. We will
highlight the latest insights into the mechanisms of how these posttranscriptional modifications influence tumour
development, maintenance, and progression. Finally, we will summarize the latest advances on the development of
small molecule inhibitors that target specific writers or erasers to rewind the epitranscriptome of a cancer cell and
their therapeutic potential.
Keywords: Cancer, Inhibitors, Anti-cancer therapy, Proliferation, Migration, Epitranscriptome, RNA modifications,
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Introduction
The epitranscriptome landscape is very complex, with
more than 170 different types of chemical modifications
of RNA described to date to decorate coding and non-
coding RNAs (ncRNAs) [1]. Their occurrence has been
well documented for over 50 years, however their func-
tion remains still widely unknown [2]. Thus, while
known since the emergence of molecular biology, RNA
modifications were only coined as the “epitranscriptome”
in 2015. The study of the function of these modifications
is now emerging and has shown to have big implications
in human pathologies [3, 4]. For example, the role of
6-methyladenosine (m6A), the most abundant and better
characterized internal modification in messenger RNA
(mRNA), is to regulate embryonic stem cells and cancer
cells self-renewal and to favour survival upon heat shock
or DNA damage [5–7]. In addition to the roles of m6A
modification in mRNAs, adenosine methylation is also
found in non-coding RNAs, such as microRNAs (miR-
NAs), long non-coding RNAs (lncRNAs), and circular
RNAs (circRNAs) regulating their biogenesis and func-
tion [8–15]. We now begin to appreciate the plethora
of molecular processes that are finely regulated by
RNA modifications ranging from RNA metabolism,
decay, splicing or translation, localization, stability,
turnover, binding to RNA binding proteins (RBPs) or
other RNAs, and thereby diversifying genetic informa-
tion. Similar to epigenetics, groups of proteins have
been identified that specifically “write” (catalyse the
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deposition of a specific modification), “erase” (catalyse
the removal of a specific modification), and “read”
(recognize and bind modified nucleotides) thereby
affecting the fate of RNA. Other modifications
have been recently documented in mRNA including
N6,2′-O-dimethyladenosine (m6Am), 5-methylcytosine
(m5C), 5-hydroxymethylcytosine (hm5C), pseudouridine
(Ψ), 1-methyladenosine (m1A) or 2'-O-ribose methylation,
although their molecular functions remain still widely
unknown [5, 16].
RNA modifications are also present in other regulatory
ncRNAs, in fact the most modified RNAs are transfer
RNA (tRNAs) and ribosomal RNAs (rRNAs) and their
modifications shape protein synthesis efficiency and
fidelity. More than 100 modifications have been described
for tRNA, being the anticodon loop one hotspot of modifi-
cations and play key roles in accurate and efficient decod-
ing in translation [17]. In rRNA, most modifications
cluster around functional sites including the decoding site
and the peptidyl transfer centre (PTC), suggesting their
functional relevance in regulating protein synthesis [18,
19]. Studies in humans, yeast, and bacteria have shown
that dynamic deposition of these modifications in rRNA
regulate cell growth, and drug and stress sensitivity by
fine-tuning translation and is a very conserved mechanism
[17, 20–22]. For instance, in yeast, flies, worms, and
humans, alterations of m5C levels in rRNA favours the
translation of stress response-decoding transcripts in
order to increase survival [23, 24]. Occurrence of Ψ resi-
dues increases in mRNA in yeast under starvation and
heat shock [25–27]. And lack of 2′-O-ribose methylations
in rRNAs decreases efficient translation and affects growth
and sensitivity to antibiotics [28]. Similarly, the overall
levels of tRNA modifications change to reprogram protein
translation by changing codon usage [29–31].
The deposition of RNA modifications is dynamic, and
thereby allows rapid cellular responses to environmental
signals [16, 25, 31–34]. The ability to adapt to changing
microenvironments such as that of stress or chemother-
apeutic drugs is crucial to ensure survival of tumour
cells, indicating that RNA modifications could play im-
portant roles in cancer. Historically, cancer has been
considered fundamentally as a disease characterized by
stepwise accumulation of genetic or epigenetic alter-
ations of different oncogenes and tumour suppressor
genes. However, compelling evidence indicates that
epitranscriptomics could also play a fundamental role in
this pathology. Through its ability to modulate many
processes of RNA metabolism, dynamic RNA modifica-
tions have been shown to be important emerging regula-
tors in cancer [3, 33, 35–38]. Although RNA
modifications are not generally considered cancer
drivers, cumulative evidence shows that their aberrant
expression is functionally related to survival,
proliferation, self-renewal, differentiation, stress adapta-
tion, invasion, and resistance to therapy, all of which are
hallmarks of cancer [24, 33, 35, 37, 39–43]. For example,
dynamic changes for multiple RNA modifications can be
observed in the urine of cancer patients [44]. Most strik-
ing it has been the extraordinary enlargement of experi-
mental evidence that implicates alterations in the
expression of m6A writers, erasers or readers are associ-
ated with increased risk of obesity and diabetes, infertil-
ity and with tumour-suppressive or tumour-promoting
scenarios [3, 45]. Other RNA modifying enzymes have
been found to be altered in cancer. For example, in an
aggressive breast cancer cell lines, 2′-O methylation ap-
peared to be hypermodified in rRNA and correlated with
altered translation [46]. Mutations in the rRNA pseudo-
uridine synthase DKC1, cause X-linked dyskeratosis con-
genita (X-DC) characterized by impaired translation,
hematopoietic stem cells differentiation failure and in-
creased cancer susceptibility [47]. Alterations in tRNA
modifications have been also reported in cancer including
m5C or 5-methoxycarbonylmethyluridine (mcm5U) and
correlate with altered protein translation [33, 48–51]. All
these studies show that aberrant RNA modifications con-
tribute to proliferation, self-renewal, migration, stress
adaptation and survival of cancer cells and suggest that
targeting aberrant posttranscriptional modifications in
cancer cells may hold promise as an efficient therapy for
tumours [52].
In this review we will discuss the molecular and cellu-
lar functions of RNA modifications in modulating gene
expression programmes, with a focus on their roles in
cancer. We further summarize here recent studies that
elucidate the therapeutic potential of targeting their ab-
errant deposition in cancer. We will focus our review
article on m6A, m5C and Ψ in coding and non-coding
RNAs as notable examples due to the advances in our
understanding of the role of these epitranscriptomic
marks in cellular functions including proliferation, self-
renewal, survival to stress or migration. In addition, ex-
pression alterations or mutations in m6A, m5C and Ψ
depositing machineries have been documented in
cancer.
6-methyladenosine
m6A deposition in coding and non-coding RNA
N6-methyladenosine (m6A), a well-known posttranscrip-
tional modification first discovered in 1974 [53, 54], has
been regarded as the most frequent internal modification
found in mRNA from viruses to mammals, but also oc-
curs in small ncRNA and lncRNA in many eukaryotic
species [11, 55]. Around 0.1–0.4% of all mRNA adenines
are methylated at position N6, representing approxi-
mately 3–5 modifications per mRNA (Fig. 1) [56, 57].
The recent advent of genome-wide m6A mapping of
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polyadenylated RNAs has yielded unprecedented insights
into the m6A-methylome landscape. Most methods for
global m6A detection rely on immunoprecipitation of
methylated RNAs using specific antibodies that recog-
nise m6A [32, 58]. Subsequent improvements using
ultraviolet crosslinking steps to bind the methylated
RNA to antibodies have allowed the identification of
m6A sites at single-nucleotide resolution [59, 60]. These
methods have revealed that this modification is enriched
at 3′ untranslated regions (3′UTRs), near stop codons,
within long internal exons, in intergenic regions, introns,
and at 5’UTRs (Fig. 1) [32, 41, 59–61].
Deposition of m6A has been also reported in ncRNAs
such as miRNA, lncRNA and circRNA [9, 14, 62–65].
Deposition in miRNA is enriched in primary miRNAs
(pri-miRNA), but not in precursor miRNAs (pre-
miRNA) and m6A marks are usually located in both
intergenic and intragenic pri-miRNAs that contain ca-
nonical METTL3 motifs [9]. As for circRNAs, despite
being derived from mRNA exons, m6A-modified cir-
cRNAs are frequently derived from exons not methyl-
ated in mRNAs [62]. LncRNAs are generally defined as
transcripts longer than 200 nucleotides, and yet despite
sharing several features with coding mRNAs such as be-
ing 5′capped, spliced and, polyadenylated, m6A residues
in lncRNAs are distributed along the whole body of the
transcript and are more present in lncRNAs that
undergo alternative splicing [65].
m6A writers
The deposition of m6A occurs into nascent pre-mRNAs
during transcription and it is carried out in the nucleus by a
multicomponent methyltransferase complex, that includes
the S-adenosyl methionine (SAM) binding protein
methyltransferase-like 3 (METTL3) and methyltransferase-
like 14 (METTL14) heterodimeric catalytic core (Fig. 2a)
[66–68]. METTL3 catalyses the conversion of adenosine
to m6A through its methyltransferase domain, while
METTL14 is responsible for the recognition of RNA
substrates, and therefore the whole METTL3-METTL14
heterodimer is required for the methylation process [69, 70].
In addition, the currently defined methyltransferase complex
is also composed of adapters. The RNA-binding motif pro-
tein 15 (RBM15) is one of these adapters and is responsible
for the initial recruitment of the complex to its target site in
the mRNA. The regulatory proteins Wilms’ tumour
1-associating protein (WTAP) and KIAA1429 (also known
as VIRMA) are responsible for the complex formation [71,
72]. The recently characterized zinc finger CCCH domain-
containing protein 13 (ZC3H13) has been found to act as a
bridge between the adaptor RBM15 and WTAP [73].
miRNAs are methylated by the METTL3-METTL14-
WTAP-RBM15/15B-KIAA1429 complex [9]. More recently,
a new study has identified a single enzyme, METTL16, as
another active m6A methyltransferase in human cells [74].
METTL16 has been shown to methylate mostly small nu-
clear RNAs, a number of intronic sites in pre-mRNAs and
in addition other ncRNAs (Fig. 2c) [15, 74, 75].
m6A erasers
Deposition of N6-methyladenosine is reversible and relies
on an orchestrated and dynamic network of specific
methyltransferases but also demethylases or “erasers”.
Two 6-methyladenosine demethylases have been iden-
tified, fat mass and obesity-associated protein (FTO)
and AlkB homolog 5 (ALKBH5), which are members
of the nonheme Fe (II)/α-ketoglutarate-dependent
dioxygenases (Figs. 1 and 2a) [76, 77]. FTO shows a
preference for demethylating N6,2′O-dimethyladeno-
sine (m6Am) but also demethylates m6A [78, 79].
Furthermore, the AlkB homolog 3 (ALKBH3), another
member of this family which preferentially acts on
Fig. 1 Schematic diagram of the location of m6A, m6Am, m5C and Ψ modifications on mRNA. Blue ribbon represents the mRNA with m7G-cap
and a poly(A) tail. ATG and STOP codons are indicated. The writers, erasers, readers and function are listed in the text box attached to each
modification. Modifications: m6A, 6-methyladenosine; m6Am, N6,2ʹ-O-dimethyladenosine; m5C, 5-methylcytosine; Ψ, pseudouridine. Proteins:
METTL, methyltransferase-like; FTO, fat mass and obesity-associated protein; PUS, pseudouridine synthase; NSUN, NOL1/NOP2/SUN domain family
member; ALyREF, Aly/REF Export Factor; ZCCHC4, zinc-finger CCHC domain-containing protein 4; ALKBH5, Alpha-Ketoglutarate-Dependent
Dioxygenase AlkB Homolog 5; YTHDC, YTH domain-containing; YTHDF, YTH domain-containing family
Nombela et al. Molecular Cancer           (2021) 20:18 Page 3 of 30
m6A in tRNAs [80]. While we start to appreciate the
complexity of the m6A methylation machinery, yet it
remains to be fully understood how the methylation
machinery selectively and dynamically targets specific
regions of the transcriptome.
m6A readers
m6A methylation acts as a unique recognition element
for reader binding proteins that drive the biochemical
processes that occurred to marked RNAs [81]. Some of
the m6A readers contain a common RNA binding do-
main, the YTH domain, which include the family of
YTH domain-containing proteins 1 and 2 (YTHDC1
and YTHDC2, respectively) and the YTH domain family
proteins 1, 2 and 3 (YTHDF1, YTHDF2 and YTHDF3,
respectively) [82, 83]. Subsequently, other readers have
been discovered; eukaryotic translation initiation factor
3 (eIF3), heterogeneous nuclear ribonucleoprotein
(HNRNPC and HNRNPA2/B1), insulin-like growth factor
(IGF2BP1, IGF2BP2, and IGF2BP3), proline-rich and
coiled-coil-containing protein 2A (PRRC2A), and the fra-
gile X mental retardation protein FMRP, among other
protein readers described to date (Figs. 1 and 2a) [8, 13,
61, 84–87].
Fig. 2 Molecular mechanism of m6A deposition in RNA, biological function and implications in human cancer. a-c m6A RNA methylation
landscape in mRNA (a) and ncRNA (b & c) mediated by writers (blue balloons), including METTL3, METTL14, WTAP, RBM15B, KIAA1429,
ZC3H13 and METTL16, erasers (pink balloons) FTO and ALKBH5 and reader proteins (yellow balloons) YTHDF1, YTHDF2, YTHDF3,
YTHDC1, YTHDC2 and HNRNPC, HNRNPG, HNRNPA2, HNRNPB1, IGF2BPs and eIF3, and their role in mRNA metabolism. d-g Aberrant
m6A deposition in mRNA and ncRNAs promotes or suppresses tumour progression through METTL3/METTL14 upregulation (d) or
downregulation (e) and FTO/ALKBH5 upregulation (f) or downregulation (g). Red arrows indicate induction. Blue arrows with flat end
represent inhibition
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Molecular function of m6A deposition in RNA
Role of m6A in mRNA
Regarding the biological function of m6A deposition, this
dependents on the protein reader that identifies and
binds the modified mRNA (Fig. 2a). For example, the
YTHDC protein subtypes are found mainly in the nu-
cleus, and specifically YTHDC1 has been described as an
alternative splicing factor of pre-mRNA [88]. YTHDC1
facilitates mRNA export too by recruiting nuclear trans-
port receptors or by binding to m6A methyltransferases
complexed with TREX mRNA export complex and
modified mRNAs [89, 90]. In contrast, YTHDF protein
subtypes are predominantly found in the cytoplasm and
regulate the fate of cytoplasmic modified mRNAs. For
example, YTHDF1 and YTHDF3 improve the efficiency
of mRNA translation [91, 92], and YTHDF2 facilitates
mRNA decay through the CC4-NOT deadenylase com-
plex [93, 94]. YTHDF3 may accelerate mRNA decay too
through interacting with YTHDF2 [92]. YTHDC2 pro-
tein can exist both inside and outside the nucleus, being
able to selectively bind to m6A mark of ncRNA, yet the
biological consequence upon binding is unknown [11].
In the cytosol, YTHDC2 affects the translation efficiency
and abundance of its target mRNAs [95]. While the evi-
dence so far has shown that m6A deposition mediate di-
verse effects through a complex network of readers, a
recent study has revealed evidence for a unifying func-
tional model of m6A readers, where m6A predominantly
influences mRNA degradation through the combined ac-
tion of three YTHDF member readers [96].
Apart from the YTHDC and YTHDF members, other
reader proteins can modulate translation or stability. For
instance, eIF3 subunits have been reported to affect ca-
nonical and non-canonical cap-dependent translation.
This protein binds preferentially to m6A within the 5′
UTR of mRNA leading to enhanced translation [61]. In
addition, evidence shows that IGF2BP promotes the sta-
bility and storage of their targeted mRNAs [87].
It must be considered too that the methylation of ade-
nines causes alterations in the secondary structure of
RNAs, which in turn may alter their interaction with
reader proteins [97]. m6A compared to A promotes the
destabilization of A/U pairings and alters the thermosta-
bility of RNA duplexes [98]. This structural change has
been already correlated with an alteration in the inter-
action between HNRNPC1 and HNRNPG with mRNA
[13, 84]. Other members of the HNRNP family, HNRN
PA2/B1 could bind directly to m6A to regulate alternative
splicing events and processing of precursor miRNAs [8].
Role of m6A in non-coding RNAs
Similar to mRNA, the presence of m6A on miRNA,
lncRNA, and circRNA can regulate their binding to
m6A-readers which in turn regulate their processing and
maturation, abundance, translation, stability, location,
function, or degradation [8–12, 99–101], but also dy-
namically regulate many physiological and pathological
processes including tumourigenesis [102–104] (Fig. 2b).
For example, the methylation of primary miRNAs (pri-
miRNAs) by METTL3 increases their binding to
HNRNPA2/B1, which interacts and enables micropro-
cessor complex unit DGCR8 to target pri-miRNAs, pro-
moting the initiation of miRNA biogenesis and their
maturation into miRNAs [8, 9]. METTL14 can directly
recruit DCGR8 on the m6A modified pri-miRNA encod-
ing for miR-126a and consequently affecting the levels of
miR-126a [12]. In addition, METTL14 has been found
to be associated with chromatin during transcriptional
elongation [105], which may suggest that METTL14
may contribute to the co-transcriptional recruitment of
the microprocessor complex on pri-miRNA transcripts.
Therefore, alternations of m6A levels by methylases or
erasers differential expression could result in significant
changes in the mature pool of miRNAs.
As recently reported m6A deposition can alter lncRNA
stability. GAS5-AS1 transcript improves its stability by
m6A when modulated by ALKBH5, however m6A can
promote GAS5 lncRNA degradation through YTHDF2
and YTHDF3 binding [99, 100]. Although it is unclear
whether lncRNA localization is also regulated by m6A, it
has been shown that overexpression of METTL3 can
significantly increase the nuclear localization of RP11
lncRNA [101]. The modification of m6A in lncRNA
could as well affect their structure and influence the in-
teractions between RNAs and between RNAs and the
proteins that regulate their specific biological functions
[11, 13, 14]. For instance, HNRNPC was found to bind
to the m6A-modified hairpin compared to the unmethy-
lated hairpin of the lncRNA MALAT1 in an “m6A
switch”-regulated manner, which indicated that m6A
modification disrupts lncRNA hairpin-stem structure
and thus promoting its binding to HNRNPC [13].
LncRNA X-inactive-specific transcript (XIST) is methyl-
ated by METTL3, and METTL3 knockdown was shown
to impair XIST-mediated transcriptional silencing of
genes on the X chromosome both in vitro and in vivo
[11]. Cytoplasmic lncRNA linc1281 is methylated at its
3′-end region, and the methylation marks are required
for the binding of let-7 through the interaction of yet
unknown proteins [14].
Regarding METTL16-mediated deposition in snRNAs,
initial studies have shown to methylate A43 position of U6
snRNA, which is found near the region that base pairs with
5′ splice sites of pre-mRNAs, suggesting that METTL16
plays an important role in mRNA splicing [15].
Interestingly, ncRNAs also play significant roles in regu-
lating the methylation levels of adenosine-6 [106, 107].
For example, in differentiating stem cells, miRNAs would
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regulate the binding of METTL3 to mRNAs, by using a
sequence pairing mechanism, and thus modulating the
abundance of m6A [107]. Also in hepatocellular
carcinoma (HCC), the inhibition of miR-145 causes an
increase in YTHDF2 expression which in turn leads to a
fall in the levels of m6A, probably due to increased mRNA
degradation [64].
While the functions of m6A deposition are currently
not fully understood, a picture begins to emerge and
shows that m6A methylation takes part in the regulation
of mRNA processing, decay, stability, splicing, polyade-
nylation, nuclear export and translation. In the case of
ncRNAs, m6A has been shown to promote their process-
ing or enhance their functions [8, 11].
The role of m6A in cancer
Numerous studies have shown that m6A deposition in
RNA plays a critical role in many physiological processes,
including circadian rhythms regulation, spermatogenesis,
embryogenesis, DNA damage and stress response, pluri-
potency and cell reprogramming [7, 36, 41, 75, 108–110].
Furthermore, emerging evidence suggests that m6A regu-
lators are also closely associated with oncogenic or
tumour suppressive functions including proliferation
[111], tumourigenesis [112], invasion [113], metastasis
[12, 114, 115] or immune system evasion [116] in
malignant tumours. Below, we summarize the main
emerging roles of m6A writers, erasers and readers in
cancer (Table 1).
Role of m6A writers in cancer
METTL3 and METTL14 expression have been reported
to promote tumourigenesis in several cancer types (Fig.
2d). For example, METTL3 is overexpressed in acute
myeloid leukaemia (AML) [117]. In this study, METTL3
was shown to methylate BCL-2, PTEN, and c-Myc
mRNAs which resulted in their increased translation,
inhibiting cell differentiation and apoptosis, and promo-
tion leukaemia progression [117]. However, the mechan-
ism of the m6A-dependent translation remains
undetermined. Furthermore, another study identified
that METTL3 expression in vivo was essential to main-
tain AML cells in an undifferentiated state, and thus
maintaining myeloid leukaemia growth [118]. In com-
parison, METTL14 was shown to act as an oncogene in
AML by increasing MYB and c-Myc mRNA stability and
translation [40]. METTL3 acts as an oncogene that facil-
itates the growth, survival, and invasion of cells in lung
and colon cancer by promoting the translation of EGFR
and TAZ [113]. METTL3 is also upregulated in breast
cancer, where it increases methylation and stability of
HBXIP mRNA, which induces cell proliferation and sur-
vival of tumour cells via inhibiting the tumour suppres-
sor let-7 g [119]. Recent studies have shown that
aberrant overexpression of m6A modifiers is observed in
colorectal cancer too. The aberrant deposition of m6A
increased miRNA-1246 expression, resulting in the
downregulation of the tumour suppressor of SPRED2
and metastasis induction [120]. Other recent studies
have reported that METTL3 is overexpressed in prostate
cancer cells, contributing to the growth and invasion of
cancer cells through SHH-GLI1 signalling [121]. In
addition, METTL3 also regulates the expression of
ITGB1, thus affecting its binding to Collagen I, the mo-
bility of tumour cells, and promoting prostate cancer
bone metastasis [122].
Despite the unanimously oncogenic functions of
METTL3 and METTL14 in all these cancer types, in
glioblastoma and HCC several reports have demon-
strated both, oncogenic and tumour suppressive roles.
Initial studies showed that m6A methylation inhibited
the growth, self-renewal, and tumourigenesis of glio-
blastoma stem cells by decreasing the stability and ex-
pression of key oncogenic transcripts such as ADAM19
[35]. In contrast, in a subsequent study, METTL3 was
found to be upregulated, and to be a predictor of poor
patient survival. In this study, METTL3 was found to in-
crease the stability and expression of SOX2 mRNA, pro-
moted the growth of glioblastoma stem cells (GSCs),
and prolonged survival in mice [123]. Similarly, in HCC
the expression of m6A writes can inversely promote or
suppress tumourigenesis. For instance, METTL14 was
initially identified as a tumour suppressor in HCC [12].
In this study, the authors showed that METTL14 expres-
sion induced an increase in pri-miR-126 expression, sup-
pressing tumour metastases [12]. Conversely, in another
study METTL3 was found upregulated and associated
with poor prognosis in patients with HCC. In another
study, METTL3 inhibited SOCS2 mRNA expression
through a m6A-YTHDF2 dependent manner [56]. From
the reported data one can conclude that the variable ex-
pression of m6A writers and their bound factors, erasers
and readers may account for differences in m6A depos-
ition levels, as well as differences in targeted RNAs,
which in turn will lead to the observed discrepancy and
controversy. Yet more studies will be necessary to pre-
cisely determine the nature of METTL3 and METTL14
in glioblastoma and HCC and to identify the factors,
pathways or tumour cell states responsible for the con-
troversial findings.
In other tumours, METTL3 and METTL14 play an
tumour suppressive role (Fig. 2e). For example, in endo-
metrial cancer, 70% of tumours exhibit a reduction in
m6A levels, either through METTL14 mutations or
downregulation of METTL3 expression. METTL3-
METTL14 complex loss leads to increased cell prolifera-
tion by upregulating the expression of members of the
AKT pathway, and thus, showing a tumour suppressor
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Table 1 Alterations in N6-methyladenosine writers, erasers and readers in cancer. AML: Acute myeloid leukaemia; HCC:
Hepatocellular Carcinoma; GSC: Glioma Stem Cells; LncRNA: long non-coding RNA
Factor/Enzyme Cancer type Alteration Mechanism Ref
Writers
METTL3 AML Upregulated METTL3 promotes translation of oncogenes’ mRNAs, inhibiting cell
differentiation and apoptosis.
[117, 118]
Bladder Cancer Upregulated METTL3 accelerates miR221/222 maturation. [104, 157,
321, 322]
Breast Cancer Upregulated METTL3 inhibits miRNA let-7 and induces proliferation and survival. [119]
Colon Cancer Upregulated METTL3 increases miRNA-1246 expression inducing metastasis. [120]
Endometrial Cancer Downregulated METTL3 regulates the expression of members of AKT pathway and inhibits
cell proliferation.
[111]
Glioblastoma Downregulated METTL3 decreases oncogene expression and inhibits the self-renewal. [35, 136]
Glioblastoma/
Gastric Cancer
Upregulated METTL3 increases the stability of oncogenic mRNAs. [123, 323]
HCC Upregulated METTL3 inhibits mRNA expression of tumour suppressors, increasing
proliferation and metastasis.
[56, 114]
Lung/Colon Cancer Upregulated METTL3 promotes oncogenes’ mRNA translation. [113]
Lung Cancer Upregulated METTL3 increases miR-143-3p expression and induces oncogenes translation. [43, 324, 325]
Melanoma Upregulated Unknown. [326, 327]
Osteosarcoma Upregulated METTL3 increases mRNA expression of oncogenes. [328]
Ovarian Cancer Upregulated METTL3 stimulates the translation of oncogenes. [329, 330]
Prostate Cancer Upregulated METTL3 increases oncogene mRNA expression. [121]
Prostate Cancer Upregulated METTL3 increases the mRNA stability of cell adhesion genes. [122]
Renal Cell
Carcinoma
Upregulated Unknown. [124, 331,
332]
METTL14 AML Upregulated METTL14 increases oncogenes’ mRNA stability and translation. [40]
Bladder Cancer Downregulated METTL14 increases oncogenes’ mRNA decay. [333]





Downregulated METTL14 regulates the expression of members of AKT pathway and inhibits
cell proliferation.
[111]





Downregulated METTL14 represses the translation of P2RX6 increasing invasion. [336]
Pancreatic Cancer Downregulated Unknown. [337]
Erasers
FTO AML Upregulated FTO enhances oncogenes’ mRNA stability. [36, 37]
Bladder Cancer Downregulated Unknown. [338]
Breast Cancer Upregulated FTO downregulates the expression of tumour suppressor genes. [134]
Cervical Cancer Upregulated FTO promotes translation of oncogenes, promoting migration and drug
resistance.
[131, 132]
Glioblastoma No change FTO regulates of oncogene expression. [35, 136]
HCC Downregulated Unknown. [339]
Lung Cancer Upregulated FTO regulates MZF1 expression. [133]
Melanoma Upregulated FTO increases stability of critical immunotherapy resistance and pro-
tumorigenic melanoma cell-intrinsic genes.
[38, 130]
Pancreatic Cancer Upregulated FTO promotes oncogene mRNA stability. [340]
ALKBH5 AML Upregulated Unknown. [341, 342]
Breast Cancer Upregulated ALKBH5 enhances mRNA stability of stem cell self-renewal genes. [135, 137]
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function in endometrial cancer [111]. Similarly, in renal
cell carcinoma, depletion of METTL3 promotes cell
proliferation, growth, and colony formation through the
PI3K-AKT-mTOR pathway activation and enhances cell
migration and invasion through the epithelial-
mesenchymal transition (EMT) pathway [124].
The implication of METTL16 in cancer is poorly under-
stood, in fact only few studies have linked METTL16 to
cancer [15, 125]. In recent studies, loss-of-function muta-
tions and expression alterations were found in colon can-
cer, suggesting a role for METTL16 in the tumourigenesis
of colorectal cancer [126, 127]. Other studies have associ-
ated METTL16 with the maturation of MALAT1 mRNA
which can act as an oncogene and a tumour suppressor in
different types of cancer [125]. In addition, given the role
of METTL16 in regulating snRNA methylation and hence
their processing, METTL16 dysregulation could favour
tumour development by inducing changes in alternative
splicing. Studies in the last decade have demonstrated the
potential role of alternative splicing in the aetiology of
cancer [128]. Indeed, the change in the expression of key
enzyme isoforms in apoptosis, metabolism, cell signalling
and resistance to therapy has been attributed to the
acquisition of the tumour phenotype too [128].
Role of m6A erasers in cancer
Dysregulation of m6A erasers have been found too asso-
ciated to cancer risk, in fact FTO polymorphisms have
been known to be associated to several human disorders
including increased risk of cancer for decades [129].
After the discovery of FTO catalytic activity, we begin to
understand the molecular mechanisms underlying FTO
oncogenic activity. Initial studies showed that FTO is
highly expressed in AML and exerts its oncogenic
function by reducing m6A levels in the mRNA of the
tumour suppressors RARA and ASB2, leading to inhib-
ition of their expression [36]. Similarly, FTO was shown
to induce GSCs growth, self-renewal, tumour progres-
sion, and was associated with poor survival through
regulation of ADAM19 (Fig. 2f) [35]. More recent
studies have linked increased expression of FTO to other
tumours. For example in melanoma, FTO expression
promotes tumourigenesis and resistance to immuno-
therapy (anti-PD-1) by directly removing m6A from
PDCD1, CXCR4, and SOX10 mRNAs, thereby increas-
ing their stability (Fig. 2f) [38, 130]. FTO is also up-
regulated in cervical cancer where it induces
resistance to chemo-radiotherapy and enhances the
response to DNA damage [131, 132]. In cervical can-
cer, FTO can activate the β-catenin pathway and in-
crease ERCC1 expression that is associated with
worse prognosis. Furthermore, FTO promotes cell mi-
gration and proliferation by positive regulation of
E2F1 and MYC [131, 132]. In lung cancer FTO is
found overexpressed and is associated with poorer
prognosis, facilitating cell proliferation and invasion,
and inhibiting apoptosis by regulating MZF1 expres-
sion (Fig. 2f) [133]. In breast cancer too, high levels
of FTO promotes cell proliferation, colony formation
and metastasis in vitro and in vivo through downreg-
ulation of BNIP3 expression [134]. The compelling
evidence clearly indicates a role for FTO in cancer,
Table 1 Alterations in N6-methyladenosine writers, erasers and readers in cancer. AML: Acute myeloid leukaemia; HCC:
Hepatocellular Carcinoma; GSC: Glioma Stem Cells; LncRNA: long non-coding RNA (Continued)
Factor/Enzyme Cancer type Alteration Mechanism Ref
Glioblastoma Upregulated ALKBH5 sustains oncogene expression. [136]
Gastric Cancer No change Binding to NEAT1 lncRNA, which promotes invasion and metastasis. [138]
Lung Cancer Downregulated ALKBH5 reduces oncogene expression and inhibits oncogenic miRNA. [343]
Osteosarcoma Upregulated ALKBH5 decreases the decay of the lncRNA PVT1. [344]
Ovarian Cancer Upregulated ALKBH5 enhances stability of oncogenes, self-renewal genes and survival
genes.
[139, 142]
Pancreatic Cancer Upregulated Unknown. [140, 141]
Readers
YTHDC2 Colon Cancer Upregulated YTHDC2 upregulates expression of pro-metastatic genes. [143]
YTHDF1 Colon Cancer Upregulated Induces Wnt-β-catenin pathway and unknown. [144, 345]
Melanoma Downregulated YTHDF1 promotes the translation of tumour suppressor genes. [146]
Ovarian Cancer Upregulated YTHDF1 increases translation of oncogenes. [145]
YTHDF2 AML Upregulated YTHDF2 reduces the stability of transcripts such as TNFRSF2. [147]
HCC Upregulated YTHDF2 inhibits SOCS2 mRNA expression. [56]
HCC Downregulated YTHDF2 promotes the degradation of EGFR mRNA. [149]
Lung Cancer Upregulated YTHDF2 promotes the translation of 6PGD mRNA. [148]
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yet although FTO has been described to remove m6A
in the mRNA of tumour suppressors or genes that
could confer resistance to immunotherapy, currently
there is insufficient evidence to confirm that the ef-
fects detected in cancer are due exclusively to its
demethylase activity.
Aberrant overexpression of ALKBH5, the second m6A
demethylase to be identified, has been also associated to
several cancer types (Fig. 2f) [135–142]. ALKBH5 has
been found overexpressed in glioblastoma and its ex-
pression is associated with poorer prognosis, and it pro-
motes GSCs proliferation and tumour progression by
enhancing FOXM1 expression [136]. In breast cancer,
ALKBH5 has been shown to promote tumourigenesis by
decreasing adenosine methylation in KLF4 and NANOG
mRNAs, enhancing their stability in breast cancer stem
cells [135, 137]. In gastric cancer, it promotes invasion
and metastasis by demethylating the lncRNA NEAT1
[138]. ALKBH5 expression is found increased in ovarian
cancer too and its expression correlates with poorer sur-
vival. The upregulated expression promotes proliferation,
invasion and autophagy through the mTOR and BLC2-
Beclin1 pathways [139, 142]. Similar to other m6A regula-
tors, ALKBH5 has been demonstrated to have a tumour
suppressive role in other tumours (Fig. 2g). For example,
in pancreatic cancer cells, loss of ALKBH5 induces in-
creased methylation of the lncRNA KCNK15-AS1, leading
to its downregulation and increased cell migration.
ALKBH5 in pancreatic cancer also has been shown to in-
hibit tumourigenesis by reducing WAF-1 levels and hin-
dering Wnt signalling activation [140, 141].
Role of m6A readers in cancer
m6A readers are also aberrantly expressed in cancer, and
their defective function has been linked to oncogenic or
tumour suppressive roles, however we begin to appreciate
only now the interplay of these RNA binding proteins,
m6A and cancer. YTHDC2 and YTHDF1 are overex-
pressed in colorectal cancer, both are associated with
poor prognosis in patients and high cell proliferation and
metastatic potential. In these tumours, YTHDC2
regulates the expression of tumour promoter genes such
as HIF1A [143]. Silencing of YTHDF1 inhibits tumouri-
genicity in vitro and tumour growth in vivo by inhibiting
the Wnt-β-catenin pathway and its expression induces re-
sistance to chemotherapy [144]. YTHDF1 is also upregu-
lated in cancer. In particular, in ovarian cancer YTHDF1
increases EIF3C translation, facilitating tumourigenesis
and metastasis [145]. In contrast, YTHDF1 acts as a
tumour suppressor in melanoma where it promotes
the translation of the tumour suppressor HINT2, thus
inhibiting tumour development [146]. In the case of
YTHDF2, its overexpression in AML has been shown
to reduce the half-life of various m6A-containing
transcripts which are involved in TNF signalling and
whose upregulation promotes cell apoptosis [147].
Furthermore, YTHDF2 was found to be upregulated
in lung cancer, and to aberrantly promote the transla-
tion of 6PGD mRNA which is critical for the promo-
tion of tumour growth [148]. Nevertheless, YTHDF2
is also capable to suppress cell proliferation, tumour
growth and activation of MEK and ERK signalling via
promoting the degradation of EGFR mRNA in HCC
cells [149].
Targeting m6A machinery in cancer
Considering the critical roles of the m6A regulatory pro-
teins in several cancer hallmarks, they are promising
therapeutic targets, specially the writers and erasers,
since their activity can be modulated by small molecules.
Although there are currently no small molecule inhibi-
tors of RNA methyltransferases, several demethylase
inhibitors have been discovered or developed by
biochemical- or cell-based small-molecule compound
library screening or chemical synthesis. Most commonly,
those developed or discovered inhibitors target FTO. In
a seminal study, Su R et al. FTO was found to be inhib-
ited by the oncometabolite R-2-hydroxyglutarate
(R-2HG) [37]. In this study, R-2HG was used to directly
inhibiting FTO in AML and glioma cells, which resulted
in increased methylation and decreased expression of
c-MYC and CEBPA mRNAs, blocking proliferation, cell
cycle, and inducing apoptosis in AML and glioma cells
[37]. Since then, other studies have attempt to develop
small-molecule inhibitors to target FTO or AKLBH5
RNA demethylases, given promising results at the pre-
clinical level. For example, the ethyl ester form of
Meclofenamic acid (MA) MA2, a US Food and Drug
Administration (FDA)-approved nonsteroidal anti-
inflammatory drug, was found to be a FTO inhibitor
which led to elevated levels of m6A modification in
mRNAs in glioblastoma cells, suppressing tumour pro-
gression and prolonging the lifespan of GSC-grafted
mice [35, 150]. In addition, based on the structures of
FTO and ALKBH5 domains other groups have designed
2-oxoglutarate and iron-dependent oxygenases (2OGX)
inhibitors to target m6A erasers [151], such as for ex-
ample the IOX3 inhibitor [152]. However the promising
inhibitors have some limitations and need to be consi-
dred before their use in the clinic. All 2-oxoglutarate
derivates are not selective and may also suppress the ac-
tivity of other Fe (II) and 2OG dependent oxygenases.
More recent studies have developed two FTO inhibitors,
namely FB23 and FB23–2, which have been shown to
suppress proliferation and promote AML cell differenti-
ation/apoptosis in vitro and significantly inhibit the pro-
gression of human AML in xenotransplanted mice [153].
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Despite the contradictory results for some types of tu-
mours, m6A regulators have shown to have wide impli-
cations in several cancer hallmarks. The controversial
results reflect however that the consequences of aberrant
m6A deposition may dependent on the cancer or cell
type context, dysregulation of other signalling pathways
and distinct set of substrates. Thus, future studies will
accurately determine the biological function of each in-
dividual m6A regulator in different types of cancer, and
they will identify each critical target transcript revealing
the exact underlying mechanism. In addition, develop-
ment of selective and clinically effective inhibitors for
m6A regulatory enzymes may provide effective thera-
peutic strategies, alone or in combination with other
therapeutic agents. For example, neoantigen-specific im-
munity was shown to be regulated through YTHDF1 in
a m6A-dependet manner. Mechanistically, transcripts
encoding lysosomal proteases were shown to be marked
by m6A and bound by YTHDF1, leading to increased
translation of lysosomal cathepsins and decreased cross-
presentation of dendritic cells, implicating YTHDF1 and
m6A as potential therapeutic targets in anticancer im-
munotherapy [116].
5-methylcytosine
m5C deposition in RNA
m5C is a conserved and prevalent mark in RNA in all life
domains. m5C is found in a wide range of RNAs but it is
most abundant in eukaryotic tRNAs and rRNAs (exten-
sively reviewed in [16]). Current global m5C detection
methods rely on the chemical reactivity of cytosines to
be deaminated in the presence of sodium bisulphite, or
immunoprecipitation methods that use either antibodies
against m5C or RNA methyltransferases previously
crosslinked to the RNA target (extensively reviewed in
[16]). RNA bisulphite sequencing is the most common
used technique to map m5C and while it has resulted ef-
fective in detecting m5C in abundant RNAs such as
tRNA and rRNA [24, 42]. In mRNA different studies ob-
tained very different results. From studies identifying
m5C sites in 8000 RNAs [154], to other studies finding
only a few methylated mRNAs [155]. These controver-
sial findings have raised the need to develop more robust
methods for truly identifying m5C depositions in mRNA
[156]. More recent studies have reported only few hun-
dred m5C sites in human and mouse transcriptomes
using an improved bisulphite sequencing method and a
novel computational approach (Fig. 1) [156, 157]. What
is still undetermined is whether this low prevalence has
biological value and it needs to be further investigated.
m5C writers
In humans, cytosine-5 methylation is catalysed by the
NOL1/NOP2/sun (Nsun) family and the DNA
methyltransferase member 2 (DNMT2, TRNA Aspartic
Acid Methyltransferase 1 or TRDMT1) [158, 159].
DNMT2, NSUN2, NSUN3 and NSUN6 all methylate
cytoplasmic tRNAs, yet with different specificity and at
different residues (Figs. 3b, 4) [42, 160–167]. For example,
NSUN2 methylates the vast majority of tRNAs at the vari-
able loop, and in leucine at the wobble position [42, 168,
169], DNMT2 methylates three tRNAs at the anti-codon
loop [161, 162, 170], and NSUN6 targets the acceptor
stem of few tRNAs [164]. NSUN2 methylates also mRNA,
ncRNAs and lncRNAS (Fig. 3a, c) [157, 168, 171–173].
NSUN3 targets tRNAs in the mitochondria, and its depos-
ition is required for the formation of 5-formylcytosine
(f5m) [160, 163, 166] (Figs. 3b, 4). NOP2 (NSUN1) and
NSUN5 are nucleolar and methylate very conserved resi-
dues in 28S rRNA, close to the peptidyl-transferase centre
[165, 174, 175] and at the interface between the large and
small subunit respectively (Fig. 3d) [165, 174, 175]. Finally,
NSUN4 targets the small subunit of mitochondrial rRNA
(Fig. 3d) [176].
m5C erasers
While writers for m5C are now well documented, the ex-
istence of m5C erasers are still under debate. Some re-
ports have however indicated that m5C can be oxidised
to generate 5-hydroxymethylcytosine (hm5C) by en-
zymes of the ten-eleven translocator family (TET) in
mRNA (Fig. 3a) [177, 178] and the formation of f5C by
Alpha-Ketoglutarate-Dependent Dioxygenase AlkB
Homolog 1 (ALKBH1) at the wobble position of mito-
chondrial tRNAs (Fig. 3b) [160, 163, 166]. While the bio-
logical relevance of f5C deposition in mitochondrial
tRNAs has been well established [160, 163, 166], the bio-
logical relevance of the low abundant hm5C deposition
in mRNAs remains yet to be determined.
Molecular function of m5C deposition in RNA
Role of m5C in non-coding RNAs
The functional consequences of m5C loss in tRNAs have
been well documented. Deposition of m5C by DNMT2
and NSUN2 protects tRNAs from endonucleolytic cleav-
age by angiogenin [42, 162, 167]. NSUN2-mediated m5C
deposition in tRNAs regulates differentiation and stress
responses in tissue and in cancer stem cells [33, 42, 179–
181]. Molecularly, 5-cytosine methylation of tRNA pro-
tects them from processing into tRNA-derived small RNA
fragments (tRFs) by angiogenin [42, 162, 167, 170, 182].
The formation of tRFs is usually induced under stress and
can repress canonical translation and favour ribosome as-
sembly in unconventional 5’ start sites found in 5’ UTR of
stress response transcripts [183]. In contrast, loss of
DNMT2-mediated methylation of tRNA at C38 causes
tRNA cleavage which leads to specific codon mistransla-
tion [167]. Similarly, deletion of rRNA cytosine-5
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methyltransferases in yeast, flies, worms, and mice are not
lethal, however, in all cases, the level of m5C deposition
plays a significant role in regulating the cellular response
to stress including drugs, DNA damage, oxidative stress,
or environmental cues [23, 175, 184]. Mechanistically,
rRNA modifications such as NSUN5-mediated methyla-
tion fine-tune the translation capacity of the ribosome by
adapting it to specifically translate mRNAs relevant in
stress [24]. m5C has also been detected in small ncRNAs
and lncRNA [154, 168, 169, 185–187]. m5C deposition on
ncRNA such as vault RNA also affects its processing into
miRNA-like regulatory small RNA [168, 171].
Role of m5C in mRNAs
Only two recent studies have reported finding readers
that bind to m5C-modified mRNAs, revealing the bio-
logical relevance and the role of m5C deposition in
mRNAs (Fig. 3a). In one report, nuclear mature methyl-
ated mRNAs at any nucleotide position interacted with
the nuclear export factor AlyREF and were more likely
to be exported to the cytoplasm [173]. More recently,
another report showed that in cancer cells NSUN2 aber-
rant methylation of oncogenic mRNAs at the 3′ UTR in-
creased their interaction with the reader protein Y-box-
binding protein 1 (YBX1), which maintained the stability
Fig. 3 Molecular mechanism of m5C deposition in RNA, biological function implication in human cancer. a-d m5C RNA deposition landscape in
mRNA (a), tRNA (b), rRNA (d), and ncRNAs (c) mediated by writers (blue balloons) NSUN2–6, DNMT2 and NOP2, erasers (pink balloons) TET and
ALKBH1, and reader proteins (yellow balloons) YBX1 and AlyREF, and their role in mRNA metabolism. e-h Aberrant m5C deposition in RNAs
promotes or suppresses tumour progression through NSUN2 upregulation in mRNA, miRNA and lncRNA (e), NSUN2 downregulation in tRNA (f),
NOP upregulation in rRNA (g) or NSUN5 downregulation in rRNA (h). Red arrows indicate induction. Blue arrows with flat end represent inhibition
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of its targeted mRNAs by recruiting ELAVL1 [157]. Des-
pite these studies, the advances in finding the preva-
lence, deposition site preference, molecular function,
writers and readers of m5C on mRNA still remain
elusive.
The role of m5C in cancer
Role of m5C writers in cancer
Over the past decade, a number of cytosine-5 methyl-
transferases have been found to be associated with vari-
ous human diseases including several cancer types
(Table 2). NOP2 overexpression was long shown to in-
crease proliferation of mouse fibroblasts (Fig. 3g) [188],
and it was found to be a valuable proliferation marker
[189]. NOP2 expression has been found to be upregu-
lated in breast, lung, prostate cancer, and gallbladder
carcinoma, and its expression correlates with poor prog-
nosis [190–192]. Mechanistically, NOP2 has been shown
to bind to the T-cell factor (TCF)-binding element of the
cyclin D1 promoter, recruiting TERC elements (telomer-
ase RNA component) and activating cyclin D1 transcrip-
tion. Whether NOP2’s methylating activity of rRNA is
involved remains unexplored [193]. NSUN2 expression al-
terations have been linked to several cancer types includ-
ing breast, skin, colon, ovarian, oesophageal, bladder,
gallbladder, gastric cancer, and head and neck squamous
carcinoma [157, 172, 194–200]. DNMT2 is upregu-
lated in hundreds of tumour samples and several
somatic mutations in DNMT2 have been identified in
different tumours types [201]. NSUN4 loci is
associated to increase risk of breast, ovarian or pros-
tate cancer and its high expression is associated with
HCC [202, 203]. Lastly, NSUN5 expression has been
found to correlate with poor survival in glioblastoma
[24] and NSUN7 high expression is associated to
shorter survival in low-grade gliomas [204].
Regarding the associated mechanisms, the methylases’
molecular role seems to be tissue and context
dependent, showing different unique substrates prefer-
ences for each cancer type, but with a unifying onco-
genic result. For example for NSUN2, in most reports its
overexpression is shown to regulate the fate of one sin-
gle transcript of tumour suppressor genes or oncogenes
and thus promoting proliferation [205]. Very recently
NSUN2 was also shown to promote tumour progression
by methylation of NMR ncRNA in oesophageal cancer
[172]. In another recent study, it was reported that aber-
rant NSUN2-mediated methylation at the 3′ UTR of
oncogenic mRNAs such as heparin-binding growth fac-
tor (HDGF) mRNA can increase their stability by inter-
acting with YBX1 (Fig. 3e) [157]. While all these reports
focused on the fate of mRNAs or other transcripts
whose m5C prevalence is low, and considering that
tRNAs are the main NSUN2 targets and are highly
methylated at C-5, it is not yet clear whether the poten-
tial role of NSUN2 in cancer might actually be mediated
by modifications of mRNA.
Regarding tRNA methylation functions, NSUN2 has
been reported to be upregulated in a population of
proliferative progenitor cells in skin tumours that rely
Fig. 4 Simplified structure of a tRNA and all known Ψ and m5C events in humans. Ψ modification is shaded in blue and m5C in purple.
The table on the right indicates the position and modification in tRNA, the human enzyme that has been identified to catalyse this
modification, the sub-cellular localization of tRNAs containing the modification. m5C, 5-methylcytosine; f5C, 5-formylcytosine Ψ,
pseudouridine; Ψ derivates: Ψm, 2ʹ-O-methylpseudouridine and m1Ψ, 1-methylpseudouridine. Proteins: PUS, pseudouridine synthase;
RPUSD, RNA pseudouridine synthase domain-containing protein; NSUN, NOL1/NOP2/SUN domain family member; DNMT2, DNA
methyltransferase 2. f5C* is formed from m5C by ALKBH1 (Alpha-Ketoglutarate-Dependent Dioxygenase AlkB Homolog 1) in mitochondrial
tRNAs. Ψ derivates are formed from Ψ by methyltransferases
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Table 2 Role of aberrant deposition of m5C in cancer. AML: Acute myeloid leukaemia; ALL: Acute lymphoblastic leukaemia; HCC:
Hepatocellular Carcinoma
Factor/Enzyme Cancer type Alteration Mechanism Ref
Writers
NOP2 Breast cancer Upregulated Unknown. [190]
Leukaemia Increased NSUN1 mediates chromatin structures that
modulate 5-AZA resistance.
[216]
Lung adenocarcinoma Upregulated Unknown. [192]
Prostate cancer Upregulated Unknown. [191]
NSUN2 Bladder cancer Upregulated NSUN2 targets HDGF 3' UTR. [157]
Skin, breast and colon cancer Upregulated Unknown. [194]
Squamous cell carcinoma Upregulated Protects tRNA from cleavage and increases cell survival [33]
Gallbladder carcinoma Upregulated NSUN2 interaction with RPL6. [197]
Gastric cancer Upregulated Repressing p57(Kip2) in an m5C-dependent manner. [200]
Head and neck squamous carcinoma Upregulated Unknown. [199]
Oesophageal squamous cell carcinoma Upregulated Increased methylation and stability of NMR lncRNA. [172]
Ovarian cancer Upregulated Unknown. [195]
Several cancers Increase copy number Unknown. [198]
NSUN3 Leukaemia Undetermined NSUN3 direct binding to hnRNPK. [216]
Lung Cancer Genomic aberrations Unknown. [346]
NSUN4 Breast, ovarian, and prostate cancer Susceptibility Loci Unknown. [202]
HCC High expression Methylation processes. [203]
NSUN5 Glioblastoma Downregulation Ribosome structural changes that lead to stress
adaptive translational programmes.
[24]
NSUN7 Low Grade Gliomas High expression Unknown. [204]
DNMT2 Leukaemia Undetermined DNMT2 direct binding to hnRNPK. [216]
Several cancer types Upregulated and
somatic mutations
Inhibition of m5C deposition in tRNAs. [201]
Erasers/5-hydroxymethylcytosine writers
TET1 Glioblastoma Upregulated Unrelated to RNA hydroxymethylation. [213]
TET2 Glioblastoma Downregulated Unrelated to RNA hydroxymethylation. [214]
AML Point mutations Unknown. [210]
TET3 Glioblastoma Downregulated Unknown. [215]
TET Family Hematologic malignancies Several Unrelated to RNA hydroxymethylation. [212]
TET1/TET2 HCC Downregulated Unrelated to RNA hydroxymethylation. [347]
ALKBH1 ALL Upregulated Unknown. [211]
Gastric cancer Upregulated Unknown. [348]
Readers
YBX1 Bladder cancer Upregulated YB1 translocation to the nucleus induces acquisition
of drug resistance by upregulating expression of
multidrug resistance-1 (MDR-1) gene.
[349]
Breast cancer Upregulated YB1 interacts and inhibits ESR1-FOXA1 complex. [350]
Several cancer types Upregulated Multifunctional oncoprotein. [351]
ALYREF HCC High expression Cell cycle regulation and mitosis. [203]
Oral squamous cell carcinoma High expression Unknown. [352]
Several cancer types High expression Unknown. [353]
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on the correct deposition of m5C onto tRNAs [33].
Unexpectedly, deletion of NSun2 in mouse cells and
mouse cancer cells led to hypomethylated tRNAs
which showed to be more vulnerable to the ribo-
nuclease angiogenin, and consequently to the accu-
mulation of 5′-tRNA fragments [33, 42, 182].
Notably, the increase cleavage of tRNAs did not re-
sulted in depletion of mature tRNAs, supporting that
cleaved tRNAs mediated the phenotypic conse-
quences. In fact, there is a growing appreciation that
biogenesis of tRNA fragments is largely induced
under stress conditions and their aberrant expression,
commonly found in cancer, may indicate important
regulatory functions in tumourigenesis (extensively
reviewed in [183]). The understanding of their func-
tion is still in its infancy, but the reported data indicate
that 5′-tRNA fragments can reprogram translation to
favour stress responses by regulating the binding of trans-
lation initiation factors to the translation initiation com-
plex [206–208]. Indeed, in Nsun2 deficient mouse cancer
cells, ribosome profiling data showed an increased transla-
tion of genes associated to stress response pathways and
decreased translation of genes associated to differentiation
[33]. Importantly, the data showed that Nsun2 deficiency
in cells blocked them in an undifferentiated and more pro-
liferative state necessary for the self-renewal of tissue or
tumour stem cells [33, 179, 181, 182]. However, prolonged
deficiency showed to increase the sensitivity to stress of
the undifferentiated cells [33, 42]. The finding was further
supported by showing that Nsun2 deficient skin tumour
initiating cells were more efficiently killed by using che-
motherapeutic agents such as 5′ FU or cisplatin, which
could be further rescued upon treatment with angiogenin
inhibitors [33]. Although the exact mechanism by which
5′-tRNA fragments directly favoured translation of
specific set of transcripts is still unknown, the study
demonstrated that the combinatory use of tRNA frag-
ment biogenesis enhancers such as NSUN2 inhibitors,
with convectional chemotherapeutic agents could re-
sult in an efficient strategy to specifically eliminate
tumour initiating cells. Thus, these and other studies
show that tumour initiating cells and cancer cells re-
quire tight control of tRNA methylation, tRNA frag-
ment biogenesis and protein synthesis [209] for
accurate cell responses and to maintain the bulk
tumour, and suggest the use of tRNA methylation in-
hibitors as potent cancer initiating cells sensitizers to
cytotoxic stress (Fig. 3f).
The contribution of tRNA modifications in survival
and differentiation is further supported by findings that
Dnmt2 deletion in mice and flies was characterized by
defects in stress responses and differentiation [162, 167].
In line with Nsun2 −/− mice phenotype, Dnmt2-
depletion in mice did not globally perturb protein
synthesis rates but rather affected specific mRNAs
through reduced translation fidelity caused by loss of
tRNA methylation [167]. Yet the potential biological im-
pact of elevated tRNA cleavage due to Dnmt2 loss or
cytosine-5 methylation inhibition remains completely
unexplored. Additional work will be necessary to unveil
the contribution of tRNA fragment abundance to the
complex phenotypes observed.
Alterations in rRNA methylation have been also linked
to cancer. NSUN5 mRNA expression is strongly associ-
ated with poor survival in glioblastoma patients. Epigen-
etic loss of NSUN5 expression in gliomas leads to rRNA
cytosine hypomethylation and to increased translation of
survival factors, rendering glioma cells sensitive to sub-
strates of the stress-related enzyme NAD(P)H quinone
dehydrogenase 1 (NQO1) (Fig. 3h) [24].
Thus, these findings highlight the importance of the
tight control of tRNA and rRNA methylation and spe-
cialised protein synthesis programmes and set the basis
to search for tRNA methylase inhibitors as a potent new
approach to treat cancer.
Role of m5C erasers in cancer
5-hydroxymethylation writers have been found altered
in cancer too. TET and ALKBH1 mutations or expres-
sion alterations are highly associated to some malignan-
cies. For example, TET2 and ALKBH1 mutations have
been associated to lymphoblastic and myeloid leukaemia
[210–212]. TET1 expression is upregulated in glioblast-
omas [213], TET2 is downregulated in gliomas [214],
and TET3 is epigenetically repressed in gliomas [215].
While mechanistically the cause has been always associ-
ated to DNA demethylation or hydroxymethylation de-
fects, TET and ALKBH1 have been shown to oxidise
m5C in RNA too, raising the question as to whether de-
fects of RNA hydroxymethylation could be also linked
to cancer.
Targeting m5C machinery in cancer
To date no specific cytosine-5 RNA methyltransferase
inhibitor has been developed. Yet, given that several
drugs designed to interfere with cytosine-5 methylation
of DNA rely on the use of chemical analogues of
cytosine, they may well interfere with RNA methylation
[50, 216]. In fact, in a study by Lyko and co-workers,
complete inhibition of Dmnt2-mediated 5-cytosine
tRNA methylation with azacytidine in cancer cells re-
duced their proliferative capacity, supporting the notion
that reduced cytosine-5 methylation of tRNAs may be
an efficient cancer therapeutic strategy [50]. Despite the
promising results and potential clinical implications, the
fact that those analogues can both inhibit RNA and
DNA methyltransferases raise awareness of the use of
this unselective drugs, which may affect the methylation
Nombela et al. Molecular Cancer           (2021) 20:18 Page 14 of 30
of multiple targets (DNA, tRNA, rRNA, mRNA, ncRNA)
and may have devastating consequences.
In line with the notion that inhibition of tRNA meth-
ylases may contribute to chemotherapy resistance,
silencing of other tRNA methyltransferases such as the
7-guanosine methylase METTL1 which also methylates
tRNAs at the variable loop of several tRNAs has shown
to increase sensitivity of cancer cells to 5’FU [217].
Pseudouridine
Pseudouridine deposition in RNA
Pseudouridine (Ψ), the C5-glycoside isomer of uridine,
was the first posttranscriptional modification discovered
and is one of the most abundant modifications of RNA
[218, 219]. Despite its discovery over seventy years ago,
we are only now beginning to uncover its biological
function [25–27, 220–223].
Pseudouridine was initially detected on yeast tRNAs
and rRNA [224, 225], and now we know that different
types of RNAs including tRNA, rRNA, small nuclear
RNAs (snRNAs), small Cajal Body-specific RNAs
(scaRNAs), miRNAs, lncRNAs are also Ψ-modified
[226]. Most importantly, with the current technological
advents which rely on chemical treatment of RNA using
soluble carbodiimide(N-Cyclohexyl-N′-(2-morpholinoethyl)
carbodiimide metho-ρ-toluenesulfonate (or CMCT) for the
generation of reverse transcription-stops, several groups
have successfully performed genome-wide mapping experi-
ments validating established targets and revealing novel sub-
strates like mRNAs (Fig. 1) [25, 26, 221]. Since then, several
seminal studies have followed discovering novel substrates
and molecular roles of Ψ [25–27, 221, 222, 227–230].
Pseudouridine synthetases
Pseudouridylation can be achieved through two distinct
mechanisms, namely RNA-independent and RNA-
dependent pseudouridylation. The RNA-dependent
mechanism relies on RNA–protein complexes known as
box H/ACA small ribonucleoproteins (snoRNPs), which
consist of a box H/ACA snoRNA and four core proteins;
dyskerin (also known as NAP57 or DKC1), non-histone
protein 2 (Nhp2), nucleolar protein 10 (Nop10) and
glycine-arginine-rich protein 1 (Gar1). In H/ACA
ncRNA is responsible for substrate recognition through
complementary base-pairing interactions with the RNA
substrate, and the catalytic activity is provided by DKC1
(Fig. 5a) (reviewed in [227]). The RNA-independent
pseudouridylation is catalysed by a single enzyme,
pseudouridine synthases (PUS), which carry both sub-
strate recognition and catalysis without an RNA tem-
plate strand (Fig. 5b). The rules governing RNA
substrate recognition by RNA-independent Ψ synthases
have only been elucidated in a few cases (for a review,
see [231]). Some of the characterized Ψ synthases have a
rather strict substrate specificity and are only able to
modify one position in only one type of cellular RNA,
such as, for instance, tRNAs. The strict substrate specifi-
city depends on the universally conserved G53UUCNAN
NC60 sequence in most tRNAs, and on the three-
dimensional structure of the TΨC loop [232]. Similar re-
sults were found by analysing the co-crystal structures of
the prokaryotic enzyme TruB with isolated tRNA stem-
loops [233]. The crystals illustrated how the enzyme core
domain makes extensive interactions with the RNA, and
how TruB requires the consensus sequence around the
TΨC loop [233]. The mechanism for enzymes with a
broader susbtrate spectrum is different. For example,
PUS1, which methylates three positions in tRNAs, relies
on two positively charged RNA-binding clefts along the
surface of the protein which uniquely interacts with the
tRNA [234]. In the case of PUS7, the sequence and two-
dimensional structure are required for substrate recogni-
tion [235]. How other Ψ synthases with a broader sub-
strate repertoire can recognize all the different substrates
with a high degree of specificity is still under study.
In eukaryotes, there are over fourteen different PUS en-
zymes, ten of these enzymes belong to the PUS family, in-
cluding PUS1-10 [227, 236]. Each of them has specific
substrates, but also share some of the substrates (Fig. 5C).
For example, PUS1 modifies tRNAs at positions 38, 39
and/or 40 [234]. PUS4 [237] and PUS10 modify too
tRNAs, but at position 55 [238]. Regarding erasers, an im-
portant difference between pseudouridylation and base
methylations is that pseudouridylation is an irreversible
modification in mammals, and instead mammals excrete
the intact nucleoside [239]. No readers have been de-
scribed to date.
Molecular function of Ψ deposition in RNA
Pseudouridylation plays different physiological roles de-
pending on the RNA that is modified, but most com-
monly experimental data confirmes an important role in
different aspects of gene expression regulation. The
presence of Ψ is capable of increasing the rigidity of the
phosphodiester backbone of the RNA and affecting its
thermodynamic stability and spatial conformation, making
short RNAs more stable [240, 241]. In snRNAs, in vitro
pseudouridylation generates RNA conformational changes
that influences the snRNA-mRNA interactions [242, 243].
In vivo studies have shown that these conformational
changes are important for the snRNA activity. For ex-
ample, the yeast U2 snRNA is pseudouridylated during
stress at positions U56 and U93 by the RNA-independent
enzyme PUS7 and a box H/ACA RNP complex (snR81),
having functional implications in the efficiency of pre-
mRNA splicing [229]. Ψ’s role in small nuclear RNAs was
thoroughly reviewed recently in [220].
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Pseudouridylation also generates structural stability to
different types of RNA, such as rRNAs, which is neces-
sary for their function [244, 245]. In rRNAs, Ψs are
found at the decoding site, mRNA channel, peptidyl
transferase centre, tRNA binding site and ribosomal sub-
unit interface, thus showing an important role for the
correct assembly and function of the ribosome and for
protein synthesis [246]. For example in yeast, alterations
or substitutions of amino acids in the Ψ synthase do-
main of Cbf5p abolish pseudouridylation of rRNA,
resulting in growth defects and reduced levels of cyto-
plasmic 40S and 60S subunits of rRNA [244]. In mouse
embryonic fibroblast cells, expression of dyskerin mu-
tants leads to altered rRNA processing, unstable second-
ary structure of rRNA and cell growth defects [245].
Another similar example occurs upon the loss or disrup-
tion of H/ACA snoRNAs that guide rRNA modification.
Pseudouridylation at position U2919 in yeast rRNA is
guided by five H/ACA snoRNAs, whose loss leads to re-
duced rRNA pseudouridylation at U2919, and impaired
18S rRNA biogenesis and growth defects in yeast [247].
In mRNAs, the incorporation of Ψ can mediate
nonsense-to-sense codon conversion facilitating the base
pairing in the ribosome decoding centre, and thus result-
ing in protein diversity [248]. Other in vitro studies have
also reported that translation of mRNAs containing pseu-
douridines is slowed down and mRNA decoding affected
compared to non-modified mRNAs [249]. In addition, Ψ-
containing mRNAs have shown higher stability in cells
undergoing stress, suggesting that increased pseudouridy-
lation increases their stability [25–27]. In fact, in vitro-
transcribed mRNAs containing pseudouridines that were
introduced in mammalian cells or into mouse tissues dis-
played enhanced stability relative to uridine-containing in
vitro-transcribed mRNA [250]. Notably, the majority of
pseudouridines in mRNA are regulated in response to
Fig. 5 Ψ deposition mechanisms and pathological implications in cancer. a Schematic illustration of RNA-dependent pseudouridylation
mechanisms. Substrate recognition is achieved by sequence and structure homology of the substrate with the structural stems and loops formed
by box H/ACA small nucleolar RNAs (snoRNA). Dyskerin (DKC1) is the catalytic unit and non-histone protein 2 (Nhp2), nucleolar protein 10
(Nop10) and glycine-arginine-rich protein 1 (Gar1) are regulatory units. The RNA substrate is represented in green. b Illustration of RNA-
independent pseudouridylation mechanisms. Substrate recognition and catalysis are performed by one single pseudouridine synthases (PUS)
(blue). c Representative scheme illustrating the target specificity for each pseudouridine synthases. The fate of each modified RNA is also
illustrated with orange arrows. Pseudouridylated RNAs may be also recognised by still unknown readers (?). d Altered expression of pseudouridine
synthases can lead to cancer. For example, reduced expression of DKC1 induces a reduction of pseudouridylation in TERC and rRNA, leading to
dysfunctional TERC and rRNA and increasing tumourigenesis. e In glioma, An increased expression of DKC1 can lead to an increased Ψ deposition
on rRNA, snRNA and TERC, and thus promoting cancer cell growth and migration. f PUS7 decreased expression leads to hypomodified tRNA-
derived fragments, leading to increased self-renewal and survival in bone marrow mononuclear cells, promoting tumourigenesis. Red arrows
indicate an increase and blue arrows a decrease of processes or enzymes
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environmental signals, but its functional role is still poorly
understood [25–27, 220–223].
In tRNAs, pseudouridylation is found at the anticodon
stem and loop, at the D stem and in a conserved at the
Ψ loop, position 55, all of which stabilize its tertiary
structure and are important for codon–anticodon base-
pairing [227] (Fig. 4). Novel insights into the role of
tRNA pseudouridylation were recently obtained using
human embryonic stem cells (hESCs) and haematopoi-
etic stem and progenitor cells (HSPCs) [230]. This work
unveiled that similar to m5C deposition at the anti-
codon and variable loops, the deposition of Ψ at the
eighth position of tRNAs by PUS7 regulated the biopro-
duction of a specific class of 18-nt 5′ tRNA fragments
containing a 5′ terminal oligoguanine motif (mTOGs).
In addition, the study showed that the presence of Ψ at
position 8 of this novel class of small ncRNAs was re-
quired for efficient biding to polyadenylate-binding pro-
tein 1 (PABPC1), an integral component of the 5′ cap
translation initiation complex, resulting in displacement
of PABPC1 from capped mRNAS and reprograming
translation [230]. Thus, the study showed that RNA
modifications, by regulating the biogenesis of a novel
class of ncRNAs, they can specialized the translation
machinery.
The role of Ψ on other RNAs remains still poorly
understood. For instance, TERC is also pseudouridylated
[26], where two specific sites of pseudouridylation have
been detected, although there is currently no evidence
that this modification may be involved in telomerase ac-
tivity [251]. In miRNA, depletion of PUS10 results in a
marked reduction of the expression levels of mature
miRNAs and concomitant accumulation of unprocessed
pri-miRNAs, but unexpectedly, this process results inde-
pendent of the catalytic activity of PUS10 [228].
In sum, Ψ deposition may confer different molecular
properties to the modified RNAs, which changes their
fate or activity. While most recent studies are focused
on Ψ modifications in mRNA, yet its role on mRNA is
still unclear. Thus, further studies will be required to
fully understand the molecular role of Ψ on mRNAs. Ψ
is highly abundant on other RNA types such as snRNA,
rRNA or tRNA, and whose role has been studied for
many years. Yet, recent findings are still revealing novel
and unexpected functions, such as the role of Ψ on
tRNA fragments, and thus indicating that other func-
tions are still to be discovered.
Role of pseudouridylated RNAs in cancer
Role of DKC1 in cancer
One of the most studied disease linked to defects in
pseudouridylation is the X-linked Dyskeratosis Conge-
nita (X-DC), associated to DKC1 inactivating mutations
[252]. Dyskerin modifies mainly rRNAs and snRNAs and
it also participates in the active telomerase complex
[219]. X-DC is characterized by defects in reticulate skin
pigmentation, nail dystrophy, and mucosal leukoplakia,
but bone marrow failure is the principal cause of early
mortality in X-DC patients [253]. Patients with X-DC
are also characterized by having higher risk for cancer
development, and expression alterations are associated
to cancer too [254]. DKC1 alterations have been found
associated to skin cancer [255], breast [256, 257], colon
[254, 258, 259], lung [254, 260], prostate [261], head and
neck [262, 263], glioma [264], HCCs [265], and specially
bone marrow failure syndromes and hematologic malig-
nancies including chronic lymphocytic leukaemia [266,
267] or multiple myeloma [268–270] (Table 3). From
the molecular point of view, DKC1 is a nucleolar protein
that participates in the stabilization of the telomerase
RNA component, necessary for telomerase activity [271,
272], and pseudouridylation of diverse rRNA residues at
important ribosome domains for tRNA and mRNA
binding, all of which are important functions in highly
proliferating cells [273]. Thus, lack of dyskerin activity
causes a reduced replicative potential and premature
ageing by an impairment of telomerase activity [251]
and impediment of ribosome translation of specific
mRNAs [274, 275], primarily affecting tissues with rapid
cell turnover (Fig. 5d). Mechanistically, it has been
shown that low levels of pseudouridylated rRNA down-
regulates the internal ribosome entry (IRES)-dependent
translation of tumour suppressors such as p53 [276],
p27 and inhibitors of apoptosis (Bcl-xL, XIAP) [274,
277]. Increased expression of vascular endothelial
growth factor has been associated to loss of DKC1 [278],
resulting their depletion in high incidence of cancer de-
velopment. Other recent studies investigating the role of
Ψ in rRNA have also supported the emergent hypothesis
of the existence of specialized ribosomes in cancer. In
liver cancer cells, aberrant expression of snoRNA24,
which mediates the pseudouridylation at U609 and U863
positions in 18S rRNA, leads to changes on tRNA selec-
tion efficiency, ribosome elongation rate and translation
efficiency influencing cancer cell survival [279]. Other
example of pseudouridine modifications in rRNA is the
reduction of m1acp3Ψ modification of rRNA found in
colorectal carcinoma, which affects the direct interaction
of tRNA with ribosomal P site, altering and deregulating
translation in cancer cells [280]
Although there is more evidence that Dyskerin acts as
a tumour suppressor [274, 277, 278, 281], in contrast,
other studies have indicated an oncogenic role. For ex-
ample, in breast cancer, decreased levels of DKC1 ex-
pression, rRNA pseudouridylation and telomere length
correlate with better prognosis [256]. In glioma, in-
creased expression of DKC1 and pseudouridylation pro-
mote glioma cell growth and migration by inducing the
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upregulated expression of gliomagenesis regulators, al-
though the direct role of increased pseudouridylation of
RNAs and gliomagenesis remains unexplored (Fig. 5e)
[264].
The data so far show that alterations in DKC1 expres-
sion or activity are significantly associated to cancer,
however the exact mechanism may be cell, tissue or
DKC1 substrate dependent. Further studies will be re-
quired to fully explore whether DKC1 has a pro-
oncogenic or tumour suppressive role.
Role in cancer of RNA-independent pseudouridine
synthetases
Despite the significant association of DKC1 activity or
expression alterations to cancer, little is known on the
role of other pseudouridylases and only few studies have
associated alterations on their expression or activity to
cancer (Table 3). For example, PUS1 mediates the inter-
action of steroid receptor RNA activator 1 (SRA1) with
retinoic acid receptor-γ (RARγ) in melanoma cells, and
with oestrogen receptor in breast cancer cell lines [282].
PUS10 is a mediator of TNF-related apoptosis inducing
ligand (TRAIL)-induced apoptosis in prostate cancer
cells [283], and genomic alterations of PUS10 locus are
significantly associated with lung cancer risk [284], al-
though it is not clear whether this effects are dependent
on pseudouridylase activity. Loss of PUS7 occurs fre-
quently in myelodysplastic syndromes, haematological
clonal disorders characterised by haematopoietic stem
cells dysfunction and high risk of transformation to
AML [285]. Mechanistically, Guzzi et al. demonstrated
that PUS7 depletion in hESC and HSPCs reduced PUS7-
mediated pseudouridylation in a special class of tRNA-
derived RNA fragments, inducing significantly higher
protein synthesis rates leading to dramatic growth and
differentiation defects (Fig. 5f) [230]. Thus this work
supports the emerging view that ESCs and cancer cells
are highly sensitive to perturbations of protein synthesis,
Table 3 Role of pseudouridylases in cancer. AML: Acute myeloid leukaemia; CLL: Chronic lymphocytic leukaemia; HCC:
Hepatocellular Carcinoma
Factor/Enzyme Cancer type Regulation Mechanism Ref
Writers
DKC1 Breast cancer Downregulated DKC1 downregulation leads to an impairment of hTR
stabilization, telomerase activity and proper rRNA
pseudouridylation.
[256, 257]
CLL Downregulated Lower telomerase activity and lower expression of
sheltering components, which facilitates telomeric
damages.
[266]
Colorectal and lung cancer Sporadic mutations Unknown. [254]
Colorectal cancer Upregulated DKC1 increases the expression of TERC and rRNA
pseudouridylation, promoting proliferation.
[258, 259]
Glioblastoma Upregulated DKC1 upregulates the expression of N-cadherin,
MMP-2, HIF1A, CDK2 and cyclin E.
[264]
Head and neck cancer Upregulated Unknown. [262, 263]
HCC Upregulated Unknown. [265]
Lung cancer Upregulated High levels of TERC, leading an increased
aggressiveness and poor prognosis.
[260]
Multiple myeloma Genomic mutation Telomere length and expression levels of small
nucleolar and small Cajal body-specific RNAs.
[268–270]
Prostate cancer Upregulated Increased abundance of several H/ACA snoRNAs. [261]
Skin cancer Sporadic mutations Unknown. [255]
Pituitary cancer Sporadic mutations Defected translation of specific mRNAs harbouring
internal ribosomal entry site (IRES) elements,
including the tumour suppressor p27.
[277]
PUS1 Melanoma and breast cancer No change Interaction of steroid receptor RNA activator 1
(SRA1) with retinoic acid receptor-γ (RARγ) in melanoma
cells and with oestrogen receptor (ER) in breast cancer
cell lines.
[282]
PUS7 Myelodysplastic syndromes/ AML Loss Reduced bioproduction of tRNA-derived fragments
leading to significantly higher protein synthesis.
[230, 285]
PUS10 Prostate cancer No change PUS10 is a coactivator of TNF-related apoptosis
inducing ligand (TRAIL)-induced apoptosis.
[283]
Lung cancer Genomic alterations Unknown. [284]
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and highlights an important role for tRNA fragment in
reprograming translation [286]. Additional work using
in vivo models and patient-derived cancer cells will be
necessary to explore the clinical implications of targeting
PUS7 loss or aberrant tRNA fragment bioproduction in
cancer.
Targeting pseudouridine synthetases in cancer
From the clinical point of view, PUSs or Ψ may serve as
potential anti-cancer targets and biomarkers. For in-
stance, high amounts of Ψ have been detected in urine
of colon, prostate or ovarian cancer patients, plasma of
ovarian patients or in salivary metabolites of oral squa-
mous cell carcinoma patients, suggesting to be a poten-
tial biomarker in liquid non-invasive biopsies for early
cancer diagnoses [261, 287–290]. Yet, while mutations
and expression alterations in DKC1 have been signifi-
cantly reported in cancer, little has been reported on the
status of other Ψ synthetases. With the advent of cancer
genome- and transcriptome-wide studies, future compu-
tational analyses will reveal the mutational and expres-
sion status of all known human Ψ synthetases.
Regarding the design of drugs or screening for small
molecules that inhibit PUSs activity, while several studies
have attempted to generate or find compounds to di-
minish DKC1 activity as potential anti-cancer treat-
ments, very little progress has followed [291–293].
Clinical trials were performed in ovarian carcinoma
[294], sarcoma [295], colorectal carcinoma [296], acute
myelogenous leukaemia [297], breast cancer [298], lung
cancer [299], melanoma [300] and other cancers [301] to
examine the effectivity as anti-cancer therapy of pyrazo-
furin, a small molecule inhibitor of the orotodine-5′-
monophosphate-decarboxylase (ODCase) which also
inhibits DKC1. In all cases pyrazofurin failed to demon-
strate efficient anti-cancer activity. However, whether
pyrazofurin could be an effective treatment for patients
with overexpressed DKC1 was not concluded from those
studies, since DKC1 expression levels were not taken
into account.
Another potential small molecule inhibitor that is
already used as effective anti-cancer agent in the clinic is
5’FU. Treatment with 5’FU is known to improve survival
in various cancers [302]. While the mechanism of action
for active metabolites of 5’FU has been always attributed
to disruption of both DNA and RNA syntheses and
DNA damage induction [302], 5’FU was shown to inhibit
pseudouridine synthases, due to the substitution of ura-
cil by the analogue 5’FU in RNAs [303, 304]. In those
studies, Samuelsson et al. demonstrated that the use of
fluorinated tRNAs generated specific and stable non-co-
valent complexes with yeast pseudouridine synthases,
thus acting as potent and irreversible inhibitor [304].
Nonetheless, 5’FU is not an universal inhibitor for all
pseudouridine synthases, in fact TruB E. Coli, and most
likely its eukaryotic homologues, cannot form covalent
adducts with fluorinated RNAs [303]. Thus, it would be
interesting to test the specificity and efficacy of 5’FU in
inhibiting mammalian pseudouridine synthases. In
addition, it would be important to determine whether
part of the associated cytotoxicity of 5’FU is due to an
overall decrease of RNA pseudouridylation or to the loss
of a particular modified RNA (e.g. rRNA).
More recent studies have used in silico approaches
which can predict possible new inhibitors. One study
predicted the use of a small molecule inhibitor based on
the disruption of the interaction of DKC1 with TERC
[293]. The virtual docking-based screen found ten mole-
cules with high affinity values, of which three resulted as
potent telomerase inhibitors in a breast cancer cell line.
In another study, Floresta et al. hypothesized that nu-
cleoside analogues such as the isoxazolidinyl derivative
5′-monophosphate could act as an inhibitor of pseudo-
uridine 5′-monophosphate glycosidases competing with
the natural substrate and hampering the glycosidic C–C
bond cleavage [292]. They indeed found that the isoxa-
zolidinyl derivative accommodated within the active site
of the enzyme with higher ligand efficiency than the nat-
ural substrate, leading to the enzyme inhibition in vitro.
While we still ignore the tumour growth inhibitory po-
tential and the therapeutic benefits of using those first
inhibitors, these studies set the basis to continue with
the search for Ψ synthetase inhibitors for cancer
treatment.
Conclusion
RNA modifications have emerged as critical posttranscrip-
tional regulators of gene expression programmes. We start
to appreciate the functional networks that the epitran-
scriptome interacts with, ranging from metabolisms [31]
to epigenetics and chromatin remodelling [24, 216] or the
immune system [116]. Despite the progress, most studies
have focused on the molecular and physiological functions
of only one mark, 6-methyladenosine on mRNA, however
the epitranscriptome embraces over 170 RNA chemical
modifications that decorate coding and ncRNAs, several
other posttranscriptional RNA processing events, and
RNA binding proteins that may be as well modified as his-
tones in DNA [1]. Thus, association studies of hundreds
of other RNA marks on coding but also ncRNAs such as
tRNA or rRNA remain to be explored.
To achieve this, we first need to develop system-
wide methods and tools for rapid and quantitative de-
tection of RNA modifications. Most of the stablished
methods rely on next-generation sequencing and, as
such, they are typically blind to nucleotide modifica-
tions. Consequently, indirect methods are required
that are based on immunoprecipitation techniques
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using specific antibodies, or enzymatic methods and
chemical labelling and unique base-modification prop-
erties of RNA pairing [305]. These methodologies
have allowed us to catalogue and identify endless
modifications with high precision and at nucleotide
resolution, yet these strategies have some limitations,
reproducibility rate is low due to technical limitations
and poor computational methods. For example, anti-
bodies used to recognize modifications such as m6A
still exhibit non-specific binding and can bind to N6,
2′-O-dimethyladenosine (m6Am) too [59]. In fact, all
antibody-related approaches suffer from poorly char-
acterized, and thus unpredictable specificity of the
antibody used for enrichment [306]. To overcome
these limitations, novel detection methods have been
introduced such as DART-seq (deamination adjacent
to RNA modification targets), an antibody-free
method for detecting m6A sites, where the cytidine
deaminase APOBEC1 is fused to the m6A-binding
YTH domain [307]. Yet, this methodology is also lim-
ited since it allows to simultaneously map only RNAs
bound to YTH domain containing readers. For m5C
detection, bisulphite-RNA sequencing is the gold
standard, yet the reproducibility is low, especially in
low abundant and unstable RNA such as mRNAs
[16]. The large initial amount of RNA required to
compensate for the high losses caused by the
treatment, the resistance to C-U conversion from
neighbouring modifications or double-stranded
sequences, the inability to differentiate from other
modifications protecting the C from the conversation
such as 5-hydroxymethylation or 3-methylcytosine,
and poor computational analysis are the most com-
mon found difficulties [16]. Yet, careful assessment of
C-U conversion together with development of statisti-
cally robust bioinformatic tools that highly refined for
data analysis are still generating contradictory results
[155, 156]. Regarding the detection of pseudouridine,
several labs have developed methodologies that rely
only the chemical treatment of RNAs with CMCT,
resulting in little overlap of pseudouridine sites on
mRNA from the different studies [25, 26, 221]. Thus,
despite to the variety of the established techniques,
the reality is that there is currently no generic and
precise method for mapping and quantifying modifi-
cations in RNA. In addition, current methods are
complex and lack of single molecule resolution. In
this regard, the emerging third-generation sequencing
technologies, such as the platforms provided by Ox-
ford Nanopore Technologies (ONT) and Pacific Bio-
sciences (PacBio) have been proposed as a new means
to directly detect RNA modifications [308]. RNA
modifications can be detected by kinetic changes of
reverse transcriptases when encountering a modified
nucleotide (PacBio) [309]. Or by current changes as
the native RNA molecule is pulled through a mem-
brane pore (ONT) [310]. Although the detection of
modifications using ONT direct RNA sequencing is
already a reality [311], yet current efforts have not
yielded an efficient and accurate RNA modification
detection algorithm, largely due to the challenges in
the alignment and re-squiggling of RNA current in-
tensities. But emerging alternative base-calling strat-
egies such as EpiNano algorithms which identifies
m6A from RNA reads with an overall accuracy of
~90%, open new avenues to explore additional RNA
modifications in the future [312].
The dynamic expression patterns of writer, reader and
eraser proteins complicate the identification of the pre-
cise functional consequences of aberrant deposition of
modifications on RNA metabolism. Thus uncovering the
complete repertoire of cellular RNA substrates and the
writers, readers, and erasers will unveil how the intricate
network of epitranscriptomic events can converge into
similar cellular processes and showing how their unbal-
anced deposition may lead to pathologies. For example,
HIF1A mRNA is stabilized by m6A deposition, while in
melanoma cells high levels of HIF1α protein are main-
tained by modifications at the U34 wobble position of
tRNAs [51, 143]. Furthermore, it will be essential to
understand the factors or signals that determine the spe-
cificity of the RNA modification writers, readers, and
erasers and how these proteins are regulated in different
cell types. For instance, METTL16 is sensitive to SAM
levels and can regulate its synthesis by modifying the
SAM synthase gene MAT2A as a feedback loop mechan-
ism [313]. In addition, we need to develop innovative
technologies for precise manipulation of the epitran-
scriptome and functional assays that enables to under-
stand their dynamic mechanisms of action of each
modified RNA, since depletion of individual RNA modi-
fier may not be sufficient to comprehensively understand
their roles. For example, while the main target for
NSUN2 are tRNAs, it still remains unclear whether the
phenotypic changes seeing upon Nsun2 deletion are
caused by decrease methylation of tRNAs, or other RNA
substrates may as well contribute to the observed pheno-
type [42, 168, 179, 181, 182].
We start to appreciate the wide range of functional
consequences of the aberrant deposition of RNA modifi-
cations in human diseases including cancer. For ex-
ample, aberrant deposition of tRNA modifications,
including Ψ and m5C, leads to perturbed accumulation
of tRNA fragments, a novel class of functional ncRNAs
whose role is associated with aberrant protein synthesis
rates and reprograming of the translational machinery in
tissue and cancer stem cell populations [33, 230]. These
findings support the current view that balanced protein
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synthesis and tight control of mRNA translation is cen-
tral to cellular processes involved in tumorigenesis [314]
and highlights a key role for tRNAs and tRNAs frag-
ments in tumourigenic processes [315]. Yet, our under-
standing on how specific species of tRNA fragments
govern these processes and the clinical implications of
their aberrant expression are still very limited. Future
studies will be necessary to decipher the molecular bases
of the translation reprograming driven by tRNA frag-
ments. Additional work will be necessary to differentiate
the contribution of global changes in tRNA pools versus
specific population tRNA-derived fragments in the
tumour promoting effect of aberrant protein synthesis
[315]. More importantly, given their association to can-
cer progression, their therapeutic potential must be ex-
plored exploiting the current advent in miRNA-based
therapeutics [316].
Recent advancements in the rapidly evolving field of
epitranscriptomics have linked the reprogramming of
components of the epitranscriptomic machinery includ-
ing writers, erasers or readers of the m6A, m5C or Ψ to
cancer. The extensive number of RNA modifications
that constitute the epitranscriptome and the reversible
nature of epitranscriptomic aberrations hold promise to
the emergence of a promising field of epitranscriptomic
therapy, which is already making progress with the re-
cent development of effective inhibitors against m6A
modifying proteins. In the last years, several seminal
studies have shed light onto the diagnostic and thera-
peutic potential of targeting the cancer epitranscriptomic
code [3, 33, 317], yet we are far from understanding
whether spatio-temporal modifications of the epitran-
scriptome can drive tumour initiation [318]. In addition,
their use as therapeutic agents remains a great challenge
due to the lack of consistent and consolidated evidence
on the oncogenic or tumour suppressive nature of for
example the aberrant deposition of m6A. The inconsist-
ent evidence may reflect the precise functional outcome
of the RNA modification on each modified RNA type,
their crosstalk with other active signalling processes and
the dynamic nature of the epitranscriptome. Identifying
accurate epitranscriptome biomarkers and defining the
oncogenic or tumour suppressive effect of a given aber-
rant modification within a specific cellular context, cell
type, cellular proliferative capacity or tumour micro-
environment will guide finding the exact molecular tar-
gets to develop selective and effective therapies for a
given tumour type.
Though aberrant expression of several methylases and
Ψ synthetases has now been described in cancer, it re-
mains unclear whether they could be efficient targets for
cancer therapy. Thus, the precise contribution of meth-
ylases and Ψ synthetases to tumour initiation, growth,
metastasis and resistance need to be further investigated.
It remains unclear the RNA target specificity of each en-
zyme and how specific modified targets can contribute
to the malignant phenotype. In addition, little is known
on the dynamics of the deposition of these modifica-
tions, their erasers and how the binding to their readers
influence the RNA metabolism and tumour cell fate.
Yet, the availability of the 3D structure of most of these
enzymes and the fact that potent and selective inhibitors
have been found [52], it is reasonable to expect that in-
hibition of these enzymes is achievable. These structures
can provide the basis for structure-guided drug design
which in combination with computational tools can be
powerful resources for the development of RNA modify-
ing enzymes inhibitors. Few small molecule inhibitors
have been described that can target specifically m6A
erasers, yet none of them have reached clinical stages
[52]. For m5C methylases, azacytidine and decitabine
(5-aza2′-deoxycytidine), which are cytidine analogues
and can inhibit any cytosine-5 methylase, have been ap-
proved for clinical use in haematological malignancies
[319]. However, their use should be taken carefully due
to the lack of specificity of these inhibitors that can in-
hibit both RNA or DNA cytosine methylases. The valid-
ation of these enzymes and their modifications as good
pharmacological targets will require the discovery of po-
tent, selective, cell-permeable inhibitors to determine
the therapeutic benefit and potential risks associated
with inhibiting these enzymes.
Treatment failure in certain settings has been attrib-
uted to the presence of sub-populations of cancer
stem cells or persister cells which are intrinsically re-
sistant to many therapeutic approaches [320]. Given
that m6A, m5C or Ψ regulate cell survival to stress in
many settings and stem cell functions, targeting them
represent a very promising opportunity to specifically
target these cells populations and reduce chemoresis-
tance and recurrence. Whether other epitranscrip-
tomics changes can lead to drug resistance is not yet
understood. This clearly opens the opportunity to ex-
plore novel avenues to develop diagnostic tools based
on epitranscriptomic signatures that allow for better
patient stratification. In addition, combinatorial thera-
peutic strategies with the potential to re-establish the
normal epitranscriptomic landscape or inhibit survival
signalling pathways are promising strategies to specif-
ically eliminate cancer stem cells. Combinatorial ther-
apies that target independent pathways may be a
better option as the possibilities for the development
of tumour drug resistance may be more limited. Un-
derstanding the machineries and factors that intro-
duce, remove, or read RNA modifications will allow
the development of novel drugs with pharmaceutical
value, not only for cancer but other complex human
pathologies that have been linked to aberrant
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deposition of RNA modifications such as diabetes,
neurological, immune and mitochondrial-linked disor-
ders [47].
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